Outcomes Associated with Treatment Change from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-1-infected Patients: a Real-world Study in Japan

Overview

Journal HIV Med

Publisher Wiley

Specialty Infectious Diseases

Date 2021 Mar 15

PMID 33720508

Citations 8

Authors

Naoki Kanda

Koh Okamoto

Hisatoshi Okumura

Makiko Mieno

Kentaro Sakashita

Teppei Sasahara

Shuji Hatakeyama

Affiliations

Soon will be listed here.

Abstract

Objectives: To investigate the impact of switching from tenofovir disoproxil fumarate (TDF)- to tenofovir alafenamide (TAF)-containing regimens on bone, kidney, serum lipids and body weight among Asian patients.

Methods: A prospective, multicentre, observational cohort study was conducted at three centres for HIV infection in Japan during 2017-2019. HIV-infected adults previously treated with TDF-containing regimens and scheduled to switch to TAF-containing regimens were included. Bone mineral density (BMD), renal markers, lipids and weight were measured consecutively from 12 months before to 12 months after the switch.

Results: Among 118 patients evaluated, the mean percentage change to spine BMD during 1 year of TAF treatment was higher than that during 1 year of TDF treatment (mean difference = 1.9%; 95% confidence interval (CI): 0.8-3.1). Urine protein and β -microglobulin levels decreased significantly after the switch, while low-density lipoprotein cholesterol and triglycerides increased. During the TDF and TAF periods, the mean weight gains were 0.2 and 1.9 kg, respectively (mean difference = 1.6 kg; 95% CI: 0.9-2.3). Subgroup analysis revealed a significant difference between the mean body weight change associated with an integrase inhibitor (INSTI) (+2.8 kg) and that associated with a non-INSTI (+1.2 kg) third agent treatment only during the TAF period.

Conclusions: Among predominantly Japanese HIV-infected patients, BMD and renal tubular markers improved, while lipid profiles worsened significantly after the switch. Weight gain during the TAF period was larger than that during the TDF period. Concurrent use of INSTI with TAF may act synergistically to gain body weight.

Citing Articles

Impact of different antiretroviral therapy regimens on bone mineral density in people living with HIV: a retrospective and longitudinal study in China.

Liang X, Zhang H, Guo M, Zhao H, Yang D, Sun R BMC Infect Dis. 2024; 24(1):1400.

PMID: 39695982 PMC: 11654311. DOI: 10.1186/s12879-024-10299-y.

Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis.

Yoo J, Jung E, Kim S, Kim Y, Kim M J Int AIDS Soc. 2024; 27(9):e26358.

PMID: 39301685 PMC: 11413498. DOI: 10.1002/jia2.26358.

Cardiometabolic health in people with HIV: expert consensus review.

Batterham R, Bedimo R, Diaz R, Guaraldi G, Lo J, Martinez E J Antimicrob Chemother. 2024; 79(6):1218-1233.

PMID: 38656584 PMC: 11144490. DOI: 10.1093/jac/dkae116.

Delayed Irreversible Fanconi Syndrome Associated With Vertebral Fracture After Tenofovir Discontinuation.

Qorban G, Alyami J, Samargandy S, Madani T Cureus. 2024; 16(1):e53280.

PMID: 38435900 PMC: 10905307. DOI: 10.7759/cureus.53280.

Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study.

Abe K, Imamura J, Sasaki A, Suzuki T, Kamio S, Obara T J Pharm Health Care Sci. 2024; 10(1):13.

PMID: 38419093 PMC: 10900624. DOI: 10.1186/s40780-024-00336-y.

References

Gallant J, Daar E, Raffi F, Brinson C, Ruane P, DeJesus E . Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind,.... Lancet HIV. 2016; 3(4):e158-65. DOI: 10.1016/S2352-3018(16)00024-2. View

Milinkovic A, Berger F, Arenas-Pinto A, Mauss S . Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. AIDS. 2019; 33(15):2387-2391. DOI: 10.1097/QAD.0000000000002350. View

Schwarze-Zander C, Piduhn H, Boesecke C, Schlabe S, Stoffel-Wagner B, Wasmuth J . Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?. HIV Med. 2020; 21(6):378-385. DOI: 10.1111/hiv.12840. View

Gomez M, Seybold U, Roider J, Harter G, Bogner J . A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017. Infection. 2018; 47(1):95-102. PMC: 7384998. DOI: 10.1007/s15010-018-1227-0. View

Bourgi K, Jenkins C, Rebeiro P, Palella F, Moore R, Altoff K . Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020; 23(4):e25484. PMC: 7159248. DOI: 10.1002/jia2.25484. View

Sax P, Erlandson K, Lake J, McComsey G, Orkin C, Esser S . Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2019; 71(6):1379-1389. PMC: 7486849. DOI: 10.1093/cid/ciz999. View

Lacey A, Savinelli S, Barco E, Macken A, Cotter A, Sheehan G . Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV. AIDS. 2020; 34(8):1161-1170. DOI: 10.1097/QAD.0000000000002541. View

Post F, Tebas P, Clarke A, Cotte L, Short W, Abram M . Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr. 2016; 74(2):180-184. PMC: 5228610. DOI: 10.1097/QAI.0000000000001186. View

Venter W, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M . Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019; 381(9):803-815. DOI: 10.1056/NEJMoa1902824. View

10.

Kim Y, Oka S, Chetchotisakd P, Clarke A, Supparatpinyo K, Avihingsanon A . Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials. HIV Res Clin Pract. 2019; 20(3):73-81. DOI: 10.1080/15284336.2019.1589232. View

11.

Tungsiripat M, Kitch D, Glesby M, Gupta S, Mellors J, Moran L . A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010; 24(11):1781-4. PMC: 2913151. DOI: 10.1097/QAD.0b013e32833ad8b4. View

12.

Taramasso L, Berruti M, Briano F, Di Biagio A . The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. AIDS. 2020; 34(6):877-881. DOI: 10.1097/QAD.0000000000002496. View

13.

Gupta S, Post F, Arribas J, Eron Jr J, Wohl D, Clarke A . Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019; 33(9):1455-1465. PMC: 6635043. DOI: 10.1097/QAD.0000000000002223. View

14.

Markowitz M, Zolopa A, Squires K, Ruane P, Coakley D, Kearney B . Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother. 2014; 69(5):1362-9. DOI: 10.1093/jac/dkt532. View

15.

Kuo P, Sun H, Chuang Y, Wu P, Liu W, Hung C . Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. Int J Infect Dis. 2019; 92:71-77. DOI: 10.1016/j.ijid.2019.12.029. View

16.

Achhra A, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S . Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2015; 17(4):255-68. DOI: 10.1111/hiv.12294. View

17.

Schafer J, Sassa K, OConnor J, Shimada A, Keith S, DeSimone J . Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide. Open Forum Infect Dis. 2019; 6(10):ofz414. PMC: 6786703. DOI: 10.1093/ofid/ofz414. View

18.

Grant P, Cotter A . Tenofovir and bone health. Curr Opin HIV AIDS. 2016; 11(3):326-32. PMC: 4844450. DOI: 10.1097/COH.0000000000000248. View

19.

Brown T, Qaqish R . Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006; 20(17):2165-74. DOI: 10.1097/QAD.0b013e32801022eb. View

20.

Yoshimura N, Muraki S, Oka H, Mabuchi A, En-yo Y, Yoshida M . Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab. 2009; 27(5):620-8. DOI: 10.1007/s00774-009-0080-8. View